Wednesday, 17 Oct 2018

You are here

Increased Risk of Depression and Anxiety in Rheumatoid Arthritis

Canadian researchers have analyzed population data and shown that the incidence and prevalence of depression, anxiety  and bipolar disorders are elevated in the rheumatoid arthritis (RA) patients compared to a matched population.

Estimates on the prevalence of depression and anxiety in RA patients vary widely in the literature. Thus, investigators analyzed population‐based administrative health data from Manitoba, Canada, to identify RA patients and a 5:1 matched control population to estimate the incidence and prevalence of depression, anxiety disorder, bipolar disorder, and schizophrenia. 

Among 10,206 incident cases of RA and 50,960 matched individuals, adjusted incidence rates were reported:

  • Depression: was higher in the RA patients (incidence rate ratio [IRR] 1.46 [95% confidence interval (95% CI) 1.35–1.58]). The lifetime and annual period prevalence of depression was also higher in RA.
  • Anxiety: was higher in RA patients (IRR 1.24 [95% CI 1.15–1.34]). The lifetime and annual period prevalence of anxiety was also higher in RA 
  • Bipolar disorder was also higher (IRR 1.21 [95% CI 1.00–1.47]).
  • Not significant: the frequency of schizophrenia did not differ between groups (IRR 0.96 [95% CI 0.61–1.50]).

The risks of depression, anxiety disorder, and bipolar disorder have not changed over time, despite substantial changes in the clinical management of RA over the 20‐year study period.

Clinicians should be aware that women and those of lower socioeconomic status are at particularly increased risk of these disorders.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Predictive Risk Factors for Uveitis in JIA

Researchers from Germany have studied a large cohort of juvenile idiopathic arthritis (JIA) patients and shown that JIA disease activity scores and laboratory biomarkers could be used to better define the group of JIA patients at high risk of uveitis onset.

Elder Rheumatoids Less Likely to Receive Biologics

Multiple studies have shown that elderly rheumatoid arthritis (RA) patients tend to be under-treated and receive DMARD therapies less often than younger RA patients. Now a VAMC study shows that the elderly are less likely to receive biologic agents yet are as likely to be subjected to glucocorticoid use.

Long-Term Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis

Only inhibitors of IL-1 (canakinumab) and IL-6 (tocilizumab) are FDA approved for use in children with systemic onset juvenile idiopathic arthritis (sJIA). Now, long-term data from the extension studies from two phase III studies shows that canakinumab yields long-term improvements with reduced glucocorticoid dosing with no new safety findings with long-term use.

Defining Refractory Rheumatoid Arthritis

Researchers from the British Society for Rheumatology Biologics (BSRBR) set out to define under what circumstances will rheumatoid arthritis (RA) patients manifest biologic disease-modifying antirheumatic drugs (bDMARDs) refractory disease.

Using the patients from the BSRBR Register (2001 to 2014) they defined patients as bDMARD refractory when they initiated their third class of bDMARD.

Venous Thromboembolism Increased with Rheumatoid Arthritis, Not with TNF Inhibition

Venous thromboembolism (VTE) is a common adverse event throughout medicine and includes both pulmonary embolism (PE) and deep vein thrombosis (DVT).   The cost of diagnosing a thromboembolic event is approximately $4000 - $5550, while the annual cost of treating one case of VTE is between $17,000 and $19,000. The impact of VTE is substantial.